Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib

J Thorac Oncol. 2018 Dec;13(12):e243-e246. doi: 10.1016/j.jtho.2018.08.2025. Epub 2018 Sep 8.

¹ Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
² Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
³ Institute of Hematopathology Hamburg (HpH), Hamburg, Germany.
⁴ Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
⁵ Thermo Fisher Scientific, Austin, Texas.
⁶ Menarini Silicon Biosystems, Bologna, Italy.
⁷ Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
⁸ Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany.
⁹ Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Tumor Biology, Center of Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: [email protected].

No abstract available

Publication types